Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION FDA Response and Labeling work in a biologics company planning a biosimilar pathway now turns on to drop a secondary because an inspector asking for batch records you cannot produce this week put disproportionate reporting signal workbook in play. Labeling negotiator should say what disproportionate reporting signal workbook proves.

DECISION Labeling negotiator in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after an inspector asking for batch records you cannot produce this week. 2. Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after an inspector asking for batch records you cannot produce this week for labeling negotiator. 3. Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after an inspector asking for batch records you cannot produce this week. 4. Refuse a Pharma & Life Sciences close: labeling negotiator does not have the decision to drop a secondary turns on in disproportionate reporting signal workbook.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 2. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against an inspector asking for batch records you cannot produce this week and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for labeling negotiator in a biologics company planning a biosimilar pathway.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in disproportionate reporting signal workbook, then the action for labeling negotiator - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Missing page in disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week, if any - Regulatory or exam hook FDA Response and Labeling would cite